- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04975880
Quanta Home Run Trial
April 9, 2024 updated by: Quanta Dialysis Technologies Ltd
A Prospective, Multi-Center, Open-Label Assessment of Efficacy and Safety of Quanta SC+ for Home Hemodialysis
The purpose of this study is to determine non-inferiority in safety and efficacy when Quanta SC+ is used in the self-care home environment compared to a hemodialysis facility.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This clinical trial is being conducted to evaluate the Quanta SC+ hemodialysis System for home use by patients with established kidney failure.
A dialysis prescription of 3 sessions per week, 4 hours per session, or facility standard will be provided during the in-clinic training period, followed by the home period with a dialysis prescription of 4 sessions per week, 3.5 hours per session.
Study Type
Interventional
Enrollment (Actual)
46
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lisa Bismarck, RN
- Phone Number: +1-978-998-9090
- Email: lisa.bismarck@quantadt.com
Study Locations
-
-
California
-
Sacramento, California, United States, 95825
- Capital Nephrology Medical Group
-
San Diego, California, United States, 92131
- Home Dialysis Therapies of San Diego / UCSD
-
San Leandro, California, United States, 94577
- Satellite WellBound
-
San Mateo, California, United States, 94403
- Satellite - WellBound
-
Santa Rosa, California, United States, 95407
- Satellite - WellBound
-
Victorville, California, United States, 92392
- High Desert Nephrology Medical Group
-
-
Florida
-
Ocala, Florida, United States, 32724
- Ocala RKCHD At Home
-
-
Georgia
-
Augusta, Georgia, United States, 30904
- Southeastern Clinical Research Institute, LLC
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- DaVita Home Dialysis of Indianapolis
-
-
New York
-
New Hyde Park, New York, United States, 11040
- New Hyde Park Dialysis Center
-
-
Pennsylvania
-
Lancaster, Pennsylvania, United States, 17604
- Hypertension & Kidney Specialists
-
-
Texas
-
Houston, Texas, United States, 77058
- aQua Research Institute, LLC
-
-
Washington
-
Seattle, Washington, United States, 98122
- Northwest Kidney Centers
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Provision of a written informed consent form signed by the participant
- Age between 18 and 80 years at time of enrollment
- A care partner must be available for training on SC+ and to be present in the home during all home hemodialysis sessions
- Participants should be either receiving regular, facility-based hemodialysis therapy for at least 90 days, or in the case of peritoneal patients transitioning to hemodialysis, at least 90 days, or performing home dialysis (with any frequency) for at least 90 days and willing to return to facility for purpose of study, and should be clinically stable and deemed suitable for home dialysis in the opinion of the principal investigator
- Willing to accept a dialysis prescription of 3 sessions per week, 4 hours each session or facility standard during in-clinic visits; 4 sessions, 3.5 hours each session during in-home sessions
- In the opinion of the Investigator, participant has well-functioning and stable vascular access (tunneled, central venous catheter, arteriovenous fistula, or graft) that allows a blood flow of at least 300 ml/min
- Home environment is adequate to ensure that appropriate electrical connections and water supply necessary for the use and storage of the device as assessed by Quanta prior to subject C1 visit. Also ensure that cellular signal and/or WIFI capacity is adequate.
- Participant or care partner are capable of understanding the nature of procedures and requirements of the study protocol and of home-based hemodialysis, and are willing and capable of complying with protocol and returning to treatment center as stated in protocol
- Participant or care partner are capable of being trained to use the machine and troubleshoot should an alarm situation occur
- In the opinion of the treating physician, the subject is able to participate in the trial in terms of social factors and personal functioning
- Acceptable physical ability of the participant and/or care partner to perform the hemodialysis treatment at home
- Financial coverage for treatment costs by Medicare, Medicaid, private insurance, or other arrangement acceptable to participant
Exclusion Criteria:
- Pregnant or trying to become pregnant (women of childbearing potential must use medically accepted contraceptive measures)
- Predicted life expectancy of less than 12 months from first study procedure
- Major cardiovascular adverse event in the 3 months prior to screening
- Fluid overload due to intractable ascites secondary to liver cirrhosis
- Uncontrolled or unstable blood pressure (systolic BP outside the range 90 to 180 mmHg)
- Unstable coronary artery disease
- New York Class III or IV heart failure, or ejection fraction less than 30%
- Participation in other clinical studies that may interfere with the current protocol
- Known problems with coagulation
- Active, life-threatening, rheumatologic disease.
- Hematocrit less than 28% at enrollment
- Hemoglobin less than 9 g/dL at enrollment
- Suffering from active severe infection
- Seroreactive for hepatitis B surface antigen
- Suffering from active malignancy with expected deteriorating course within 6-12 months
- History of severe reactions to dialyzer membrane material
- Expected to receive an organ transplant during the course of the study
- Have dementia or inability to understand procedures
- Lack an ability for self-care
- Are non-adherent to their current dialysis treatments
- Experience intra-dialytic hypotension defined as a decrease in systolic blood pressure of greater than or equal to 20 mmHg or a decrease in mean arterial pressure of greater than or equal to 10 mmHg provided that the decrease is associated with clinical events (symptoms) and the need for an intervention (ultrafiltration turned off, bolus of fluid) in 3 of 5 previous treatments
- Is intolerant to heparin
- Considered in the investigator's opinion to be clinically unstable for any other reason
- Undergoing outpatient dialysis for the treatment of acute kidney injury (AKI)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Hemodialysis Treatments
All subjects will receive hemodialysis treatments using the SC+ machine for all phases of the trial including in-clinic training, transition, and in the home setting.
|
Following the in-clinic training phase and one week transition, the intervention of self or care partner hemodialysis delivered in the home setting will occur for 8 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Standardized Weekly Kt/V (Efficacy)
Time Frame: 8 weeks per period
|
Mean standardized weekly Kt/V greater than or equal to 2.1, using a hemodialysis prescription of 4 sessions per week for 3.5 hours per session, measured for dialysis delivered during the home portion of the study.
|
8 weeks per period
|
Adverse Event Rate
Time Frame: 8 weeks per period
|
Adverse event rate: the number of adverse events per 100 treatments that occurred during the study, as defined by:
|
8 weeks per period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of SAEs and device-related SAEs
Time Frame: 8 weeks per period
|
Specific hematology laboratory values will be collected and compared to target ranges from clinical practice guidelines. |
8 weeks per period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Paul Komenda, MD, Quanta Dialysis Technology
- Principal Investigator: Christopher T Chan, MD, University of Toronto
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 18, 2021
Primary Completion (Actual)
October 30, 2023
Study Completion (Estimated)
October 1, 2024
Study Registration Dates
First Submitted
July 14, 2021
First Submitted That Met QC Criteria
July 14, 2021
First Posted (Actual)
July 26, 2021
Study Record Updates
Last Update Posted (Actual)
April 11, 2024
Last Update Submitted That Met QC Criteria
April 9, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 02-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Failure
-
University of Sao Paulo General HospitalUnknownRenal Transplant Rejection | Graft Failure | Transplant; Failure, Kidney | Chronic Renal Failure (CRF)Brazil
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Puerto Rico
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Canada
-
Angiodynamics, Inc.TerminatedChronic Kidney Disease | Acute Kidney Injury | Acute Renal Failure | Renal Failure Chronic Contrast InducedUnited States
-
University Hospital, Clermont-FerrandRecruitingAcute Kidney Injury | Transient Acute Renal Failure | Persistent Acute Renal FailureFrance
-
University Hospital, GhentCompletedAcute Renal Failure | Chronic Renal FailureBelgium
-
The University of Hong KongHospital Authority, Hong KongCompletedEnd-stage Renal Failure (ESRF)Hong Kong
-
Washington University School of MedicineCompletedAcute Renal Failure | Chronic Renal FailureUnited States
-
The Hong Kong Polytechnic UniversityHospital Authority, Hong KongCompletedPalliative Care | Renal Failure, End-stageHong Kong
-
PfizerCompletedChronic Renal Failure Requiring HemodialysisUnited States, Puerto Rico
Clinical Trials on SC+ Hemodialysis System
-
Baxter Healthcare CorporationGambro Dasco S.p.A.Completed
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
Outset MedicalCompleted
-
Outset MedicalRecruiting
-
Qidni Labs Inc.RecruitingKidney Disease, End-StageCanada
-
Deka Research and DevelopmentCVS Kidney Care LLC.Active, not recruitingEnd Stage Renal DiseaseUnited States
-
Deka Research and DevelopmentCVS Kidney Care LLC.CompletedEnd-Stage Renal DiseaseUnited States
-
Nikkiso America, Inc.NAMSACompletedDialysis | Chronic Renal FailureUnited States
-
Beaumont HospitalBaxter Healthcare CorporationUnknownSleep Disorders | Renal Failure Chronic Requiring HemodialysisIreland
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...RecruitingEnd Stage Renal Disease on DialysisItaly